Physician profile
Jerry Mark Smith
NPI 1649581059
$4,460.77
in general payments reported to CMS, 2019-2025
30 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $566 · 2021: $934 · 2022: $364 · 2023: $549 · 2024: $548 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.46 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.19 | 2019-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $529.35 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $470.10 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $395.49 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $292.32 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $270.23 | 2019-2025 | |
| Genentech USA, INC. | $236.93 | 2019-2023 | Erivedge |
| Misonix INC | $164.70 | 2021 | |
| Vector Surgical, LLC | $150.00 | 2021 | |
| Amgen INC. | $149.09 | 2020-2025 | Otezla, Otezla |
| Biofrontera INC. | $138.14 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Merz North America, INC. | $125.00 | 2019 | |
| Ucb, INC. | $114.94 | 2020-2025 | Bimzelx |
| Genzyme Corporation | $80.63 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.24 | 2021-2025 | Jublia, Cabtreo, Arazlo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $76.09 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kyowa Kirin, INC. | $74.03 | 2023-2024 | Poteligeo |
| Incyte Corporation | $72.36 | 2024-2025 | Opzelura |
| Convatec INC. | $66.85 | 2025 | |
| Almirall LLC | $51.10 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $47.49 | 2020-2022 | |
| Epi Health, LLC | $47.04 | 2020-2022 | |
| Galderma Laboratories, L.P. | $41.73 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.64 | 2025 | Spevigo |
| Leo Pharma INC. | $19.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.87 | 2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $18.77 | 2025 | Zoryve |
| Dermira, INC. | $16.15 | 2021 | |
| Pfizer INC. | $16.02 | 2019 | |
| Smith+Nephew, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.